Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2022

Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program

Bastien Collomb
Amélie Dubromel
Anne Gaëlle Caffin
  • Fonction : Auteur
Chloé Herledan
  • Fonction : Auteur
Virginie Larbre
  • Fonction : Auteur
Amandine Baudouin
  • Fonction : Auteur
Ariane Cerutti
  • Fonction : Auteur
Laurence Couturier
  • Fonction : Auteur
Magali Maire
  • Fonction : Auteur
Lionel Karlin
  • Fonction : Auteur
Laure Huot
Stéphane Dalle
Emmanuel Bachy
Hervé Ghesquieres
  • Fonction : Auteur
Gilles Salles
  • Fonction : Auteur
Sébastien Couraud
  • Fonction : Auteur
Benoit You
Gilles Freyer
  • Fonction : Auteur
Véronique Trillet-Lenoir
  • Fonction : Auteur
Florence Ranchon
Catherine Rioufol
  • Fonction : Auteur

Résumé

Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treated by oral anticancer agents (OAAs) using PROs. Methods Between September 2018 and May 2019, outpatients starting OAAs were included in a 12-week follow-up to assess 15 symptoms listed in the National Cancer Institute PRO Common Terminology Criteria for Adverse Events, using a 5-point scale of severity or frequency. Patients were requested to alert a referral nurse or pharmacist when they self-assessed high-level (level 3 or 4) symptoms. Results 407 questionnaires were completed by 63 patients in which 2333 symptoms were reported. Almost three-quarters (74.6%) reported at least one high-level symptom. The symptoms that were most commonly experienced were fatigue (>9 in 10 patients; 13.2% of symptoms declared), various psychological disorders (>9 in 10 patients; 28.6% of symptoms declared) and general pain (>8 in 10 patients; 9.4% of symptoms declared). Conclusion PROs are appropriate to detect potential adverse events in cancer outpatients treated by OAAs. This study is the first step for integrating the patient’s perspective in a digital e-health device in routine oncology care.

Dates et versions

hal-04150994 , version 1 (04-07-2023)

Identifiants

Citer

Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, Chloé Herledan, Virginie Larbre, et al.. Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14 (3), pp.660. ⟨10.3390/cancers14030660⟩. ⟨hal-04150994⟩

Collections

HCL
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More